Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1994 5
1995 4
1996 7
1997 3
1998 6
1999 4
2000 12
2001 9
2002 14
2003 16
2004 23
2005 24
2006 19
2007 22
2008 22
2009 23
2010 20
2011 18
2012 8
2013 13
2014 11
2015 9
2016 12
2017 5
2018 12
2019 4
2020 2
2021 9
2022 10
2023 5
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

319 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D; STEP 4 Investigators. Rubino D, et al. JAMA. 2021 Apr 13;325(14):1414-1425. doi: 10.1001/jama.2021.3224. JAMA. 2021. PMID: 33755728 Free PMC article. Clinical Trial.
Treatment of obesity and metabolic-associated fatty liver disease with a diet or orlistat: A randomized controlled trial.
Feng X, Lin Y, Zhuo S, Dong Z, Shao C, Ye J, Zhong B. Feng X, et al. Am J Clin Nutr. 2023 Apr;117(4):691-700. doi: 10.1016/j.ajcnut.2023.02.008. Epub 2023 Feb 11. Am J Clin Nutr. 2023. PMID: 36781126 Free article. Clinical Trial.
RESULTS: A total of 118 subjects with obesity and MAFLD were randomly assigned to the control group (n = 39), the orlistat group (n = 40), or the experimental diet group (n = 39). All 3 groups demonstrated improvement in liver steatosis at wk 24. The absolute decrease in L …
RESULTS: A total of 118 subjects with obesity and MAFLD were randomly assigned to the control group (n = 39), the orlistat group (n = …
Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.
Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf M. Sjöström L, et al. Lancet. 1998 Jul 18;352(9123):167-72. doi: 10.1016/s0140-6736(97)11509-4. Lancet. 1998. PMID: 9683204 Clinical Trial.
Total cholesterol, low-density lipoprotein (LDL) cholesterol, LDL/high-density lipoprotein ratio, and concentrations of glucose and insulin decreased more in the orlistat group than in the placebo group. Gastrointestinal adverse events were more common in the orlistat …
Total cholesterol, low-density lipoprotein (LDL) cholesterol, LDL/high-density lipoprotein ratio, and concentrations of glucose and insulin …
XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.
Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. Torgerson JS, et al. Diabetes Care. 2004 Jan;27(1):155-61. doi: 10.2337/diacare.27.1.155. Diabetes Care. 2004. PMID: 14693982 Clinical Trial.
After 4 years' treatment, the cumulative incidence of diabetes was 9.0% with placebo and 6.2% with orlistat, corresponding to a risk reduction of 37.3% (P = 0.0032). ...Mean weight loss after 4 years was significantly greater with orlistat (5.8 vs. 3.0 kg with place …
After 4 years' treatment, the cumulative incidence of diabetes was 9.0% with placebo and 6.2% with orlistat, corresponding to a risk …
Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Khera R, et al. JAMA. 2016 Jun 14;315(22):2424-34. doi: 10.1001/jama.2016.7602. JAMA. 2016. PMID: 27299618 Free PMC article. Review.
STUDY SELECTION: Randomized clinical trials conducted among overweight and obese adults treated with US Food and Drug Administration-approved long-term weight loss agents (orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, or liraglutide) for at least 1 ye …
STUDY SELECTION: Randomized clinical trials conducted among overweight and obese adults treated with US Food and Drug Administration-approve …
Effect of orlistat on plasma lipids and body weight: A systematic review and meta-analysis of 33 randomized controlled trials.
Sahebkar A, Simental-Mendía LE, Reiner Ž, Kovanen PT, Simental-Mendía M, Bianconi V, Pirro M. Sahebkar A, et al. Pharmacol Res. 2017 Aug;122:53-65. doi: 10.1016/j.phrs.2017.05.022. Epub 2017 May 27. Pharmacol Res. 2017. PMID: 28559211 Review.
Orlistat, an inhibitor of intestinal lipase, promotes body weight reduction. The lipid-lowering efficacy of orlistat is controversial and the effect of orlistat-induced body weight reduction on lipid changes has not been explored in meta-regression analyses. …
Orlistat, an inhibitor of intestinal lipase, promotes body weight reduction. The lipid-lowering efficacy of orlistat is contro …
The Effect of Orlistat on Sterol Metabolism in Obese Patients.
Kwon YJ, Kwon GE, Lee HS, Choi MH, Lee JW. Kwon YJ, et al. Front Endocrinol (Lausanne). 2022 Feb 23;13:824269. doi: 10.3389/fendo.2022.824269. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35282441 Free PMC article. Clinical Trial.
BACKGROUND: Orlistat, a reversible inhibitor of pancreatic and gastric lipase, is known to have anti-obesity and antioxidant properties. ...Our findings support that orlistat plays a crucial role in the process of endothelial dysfunction and atherosclerosis via oxys …
BACKGROUND: Orlistat, a reversible inhibitor of pancreatic and gastric lipase, is known to have anti-obesity and antioxidant properti …
A systematic review of the clinical effectiveness of orlistat used for the management of obesity.
O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G. O'Meara S, et al. Obes Rev. 2004 Feb;5(1):51-68. doi: 10.1111/j.1467-789x.2004.00125.x. Obes Rev. 2004. PMID: 14969507 Review.
The aim of this paper is to assess the clinical effectiveness of orlistat used for the management of obesity. Nineteen electronic databases were searched for randomized controlled trials evaluating the effectiveness of orlistat for weight loss or maintenance of weig …
The aim of this paper is to assess the clinical effectiveness of orlistat used for the management of obesity. Nineteen electronic dat …
Orlistat mouth rinse: Using the tongue to deliver antiobesity medication in a double-blind randomized crossover pilot trial.
Primeaux SD, Dubin R, Greenway FL. Primeaux SD, et al. Diabetes Obes Metab. 2023 Aug;25(8):2236-2242. doi: 10.1111/dom.15101. Epub 2023 May 3. Diabetes Obes Metab. 2023. PMID: 37132340 Free PMC article. Clinical Trial.
AIM: To investigate the effects of an orlistat mouth rinse on the intake of a high-fat meal. METHODS: A double-blind, balanced order, crossover study was conducted in participants (n = 10, body mass index 25-30 kg/m(2) ) assigned to receive placebo or orlistat (24 m …
AIM: To investigate the effects of an orlistat mouth rinse on the intake of a high-fat meal. METHODS: A double-blind, balanced order, …
319 results

Searches related to "orlistat"